{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:31:10Z","timestamp":1782189070490,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Antik\u00f6rper-Wirkstoff-Konjugate (\u201eantibody-drug conjugates\u201c [ADCs]) sind eine Klasse zielgerichteter Krebstherapien, die aus einem monoklonalen Antik\u00f6rper, einem Verbindungsmolek\u00fcl (Linker) und einem zytotoxischen Wirkstoff bestehen. Unerw\u00fcnschte Ereignisse (UE) am Auge treten bei ADCs mit Tubulin-gerichteten Wirkstoffen wie Belantamab-Mafodotin, Tisotumab vedotin und Mirvetuximab-Soravtansin (MIRV) h\u00e4ufig auf. MIRV zielt auf den Folatrezeptor alpha (FR\u03b1) ab und verf\u00fcgt \u00fcber einen Tubulin-gerichteten Wirkstoff (das Maytansinoid DM4). MIRV erhielt die vollst\u00e4ndige Zulassung in den USA (M\u00e4rz 2024) f\u00fcr das FR\u03b1-positive platinresistente Ovarialkarzinom (PROC) und ist der erste neuartige Wirkstoff, der in einer Phase-III-PROC-Studie einen signifikanten \u00dcberlebensvorteil im Vergleich zur Einzelwirkstoffchemotherapie zeigte. MIRV wurde k\u00fcrzlich von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) f\u00fcr die gleiche Indikation zugelassen, die in der klinischen Pr\u00fcfung MIRASOL beurteilt wurde. UE der Augen, die mit MIRV im Zusammenhang stehen, umfassen prim\u00e4r verschwommenes Sehen und Keratopathie aufgrund vor\u00fcbergehender Hornhautver\u00e4nderungen. Es wird jedoch angenommen, dass der Mechanismus, durch den MIRV unerw\u00fcnschte Ereignisse der Augen verursacht, auf Wirkungen an nicht beabsichtigten Zielstrukturen (\u201eOff-Target\u201c) oder die unspezifische Aufnahme durch das Epithel der Hornhaut zur\u00fcckzuf\u00fchren ist. Die Ergebnisse der klinischen Pr\u00fcfungen zu MIRV zeigen, dass diese UE reversibel sind und es Strategien zur \u00dcberwachung\/Vorbeugung (Prophylaxe) gibt, um ihre Inzidenz bzw. therapeutische Konsequenzen zu senken. Dazu geh\u00f6ren prophylaktische Kortikosteroidaugentropfen, t\u00e4glich angewandte befeuchtende Augentropfen, Dosismodifikationen  und regelm\u00e4\u00dfige Augenuntersuchungen. Die Unterst\u00fctzung durch Augen\u00e4rzte ist f\u00fcr die Behandlung von UE unerl\u00e4sslich, um die MIRV-Therapie fortsetzen zu k\u00f6nnen. Diese \u00dcbersicht bietet Augen\u00e4rzten einen klinischen \u00dcberblick \u00fcber UE der Augen, die mit bestimmten auf Tubulin-gerichteten ADCs in Zusammenhang stehen. Der Schwerpunkt liegt hierbei auf MIRV und den prophylaktischen\/symptomlindernden Ma\u00dfnahmen, die den Patientinnen eine Verl\u00e4ngerung der MIRV-Therapie erm\u00f6glichen.<\/jats:p>","DOI":"10.1007\/s00347-025-02306-7","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:15:07Z","timestamp":1756804507000},"page":"803-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Korneale Nebenwirkungen von Mirvetuximab-Soravtansin","Corneal events with mirvetuximab soravtansine"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-7773","authenticated-orcid":false,"given":"Ramin","family":"Khoramnia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"e390094","DOI":"10.1200\/edbk_390094","volume":"43","author":"M Shastry","year":"2023","unstructured":"Shastry\u00a0M, Gupta\u00a0A, Chandarlapaty\u00a0S et\u00a0al (2023) Rise of antibody-drug conjugates: the present and future. Am Soc Clin Oncol Educ Book 43:e390094. https:\/\/doi.org\/10.1200\/edbk_390094","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2306_CR2","volume-title":"Prescribing information","author":"Blenrep","year":"2022","unstructured":"Blenrep (2022) Prescribing information. GlaxoSmithKline"},{"key":"2306_CR3","volume-title":"Prescribing information","author":"Elahere","year":"2024","unstructured":"Elahere (2025) Prescribing information. AbbVie"},{"key":"2306_CR4","volume-title":"Prescribing information","author":"Tivdak","year":"2024","unstructured":"Tivdak (2024) Prescribing information. Seagen Inc"},{"key":"2306_CR5","doi-asserted-by":"publisher","first-page":"101155","DOI":"10.1016\/j.gore.2023.101155","volume":"47","author":"A Hendershot","year":"2023","unstructured":"Hendershot\u00a0A, Slabaugh\u00a0M, Riaz\u00a0KM et\u00a0al (2023) Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep 47:101155. https:\/\/doi.org\/10.1016\/j.gore.2023.101155","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"2306_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00347-022-01660-0","volume":"120","author":"VA Augustin","year":"2023","unstructured":"Augustin\u00a0VA, Bl\u00f6ck\u00a0L, Hegenbart\u00a0U et\u00a0al (2023) Belantamab mafodotin-assoziierte keratopathie \u2013 eine h\u00e4ufige und therapiebeeinflussende nebenwirkung. Ophthalmologie 120(4):418\u2013422. https:\/\/doi.org\/10.1007\/s00347-022-01660-0","journal-title":"Ophthalmologie"},{"issue":"10","key":"2306_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton\u00a0JS, Miller\u00a0PE, Mannis\u00a0MJ et\u00a0al (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J\u00a0Ocul Pharmacol Ther 31(10):589\u2013604. https:\/\/doi.org\/10.1089\/jop.2015.0064","journal-title":"J Ocul Pharmacol Ther"},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","volume":"242","author":"J Aschauer","year":"2022","unstructured":"Aschauer\u00a0J, Donner\u00a0R, Lammer\u00a0J et\u00a0al (2022) Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy. Am J Ophthalmol 242:116\u2013124. https:\/\/doi.org\/10.1016\/j.ajo.2022.06.009","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2306_CR9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.Mct-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab\u00a0O, Whiteman\u00a0KR, Bartle\u00a0LM et\u00a0al (2015) IMGN853, a\u00a0folate receptor-\u237a (FR\u237a)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u237a-expressing tumors. Mol Cancer Ther 14(7):1605\u20131613. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-1095","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2306_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore\u00a0KN, Martin\u00a0LP, O\u2019Malley\u00a0DM et\u00a0al (2017) Safety and activity of mirvetuximab soravtansine (IMGN853), a\u00a0folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a\u00a0phase\u00a0I expansion study. J\u00a0Clin Oncol 35(10):1112\u20131118. https:\/\/doi.org\/10.1200\/jco.2016.69.9538","journal-title":"J Clin Oncol"},{"issue":"3","key":"2306_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F, Laversanne\u00a0M, Sung\u00a0H et\u00a0al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"2306_CR12","unstructured":"World Health Organization, International Agency for Research on Cancer https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/276-germany-fact-sheet.pdf. Zugegriffen: 29. Mai 2025"},{"issue":"23","key":"2306_CR13","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore\u00a0KN, Angelergues\u00a0A, Konecny\u00a0GE et\u00a0al (2023) Mirvetuximab soravtansine in FR\u237a-positive, platinum-resistant ovarian cancer. N\u00a0Engl J Med 389(23):2162\u20132174. https:\/\/doi.org\/10.1056\/NEJMoa2309169","journal-title":"N Engl J Med"},{"key":"2306_CR14","first-page":"7","volume-title":"Health-related quality of life in patients with FR\u237a positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator\u2019s choice chemotherapy: analysis from the phase\u00a03 MIRASOL trial","author":"Y Garcia-Garcia","year":"2024","unstructured":"Garcia-Garcia\u00a0Y, Van Gorp\u00a0T, Konecny\u00a0GE et\u00a0al (2024) Health-related quality of life in patients with FR\u237a positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator\u2019s choice chemotherapy: analysis from the phase\u00a03 MIRASOL trial. March, Barcelona, Spain, S\u00a07\u201310 (Presented at: 2024 European Society of Gynaecological Oncology)"},{"issue":"191","key":"2306_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","volume":"2024","author":"KN Moore","year":"2024","unstructured":"Moore\u00a0KN, Lorusso\u00a0D, Oaknin\u00a0A et\u00a0al (2024) Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary. Gynecol Oncol 2024(191):249\u2013258. https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.013","journal-title":"Gynecol Oncol"},{"key":"2306_CR16","unstructured":"ImmunoGen announces European Medicines Agency acceptance of Marketing Authorization Application for mirvetuximab soravtansine in platinum-resistant ovarian cancer. News release. ImmunoGen Inc. https:\/\/news.abbvie.com\/2023-10-27-ImmunoGen-Announces-European-Medicines-Agency-Acceptance-of-Marketing-Authorization-Application-for-Mirvetuximab-Soravtansine-in-Platinum-Resistant-Ovarian-Cancer. Zugegriffen: 29. Mai 2025"},{"issue":"6","key":"2306_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.ccr-18-2474","volume":"25","author":"UA Matulonis","year":"2019","unstructured":"Matulonis\u00a0UA, Birrer\u00a0MJ, O\u2019Malley\u00a0DM et\u00a0al (2019) Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res 25(6):1727\u20131736. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-2474","journal-title":"Clin Cancer Res"},{"key":"2306_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16250","author":"YP Tu","year":"2025","unstructured":"Tu\u00a0YP, Lagraauw\u00a0HM, Method\u00a0M et\u00a0al (2025) Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-alpha-positive ovarian cancer: justification of therapeutic dose regimen. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.16250","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"2306_CR19","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/jco.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis\u00a0UA, Lorusso\u00a0D, Oaknin\u00a0A et\u00a0al (2023) Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA Study. J\u00a0Clin Oncol 41(13):2436\u20132445. https:\/\/doi.org\/10.1200\/jco.22.01900","journal-title":"J Clin Oncol"},{"issue":"8","key":"2306_CR20","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472.Can-17-3202","volume":"78","author":"H Zhao","year":"2018","unstructured":"Zhao\u00a0H, Atkinson\u00a0J, Gulesserian\u00a0S et\u00a0al (2018) Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res 78(8):2115\u20132126. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3202","journal-title":"Cancer Res"},{"issue":"6","key":"2306_CR21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","volume":"41","author":"J Canestraro","year":"2022","unstructured":"Canestraro\u00a0J, Hultcrantz\u00a0M, Modi\u00a0S et\u00a0al (2022) Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates. Cornea 41(6):792\u2013801. https:\/\/doi.org\/10.1097\/ICO.0000000000002934","journal-title":"Cornea"},{"issue":"4","key":"2306_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq\u00a0AV, Degli Esposti\u00a0S, Popat\u00a0R et\u00a0al (2020) Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2\u00a0study. Ophthalmol Ther 9(4):889\u2013911. https:\/\/doi.org\/10.1007\/s40123-020-00280-8","journal-title":"Ophthalmol Ther"},{"key":"2306_CR23","unstructured":"(2024) FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. US Food & Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Zugegriffen: 29. Mai 2025"},{"key":"2306_CR24","unstructured":"(2024) AbbVie receives European Commission approval of ELAHERE\u00ae (mirvetuximab soravtansine) for the treatment of platinum-resistant ovarian cancer. News release. AbbVie. https:\/\/news.abbvie.com\/2024-11-18-AbbVie-Receives-European-Commission-Approval-of-ELAHERE-R-mirvetuximab-soravtansine-for-the-Treatment-of-Platinum-Resistant-Ovarian-Cancer. Zugegriffen: 29. Mai 2025"},{"key":"2306_CR25","unstructured":"(2024) FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. US Food & Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer. Zugegriffen: 29. Mai 2025"},{"key":"2306_CR26","unstructured":"Tisotumab vedotin Marketing Authorization Application validated by European Medicines Agency for treatment of recurrent or metastatic cervical cancer. News release. Pfizer Inc. https:\/\/www.pfizer.com\/news\/announcements\/tisotumab-vedotin-marketing-authorization-application-validated-european. Zugegriffen: 29. Mai 2025"},{"issue":"2","key":"2306_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/ico.0000000000001805","volume":"38","author":"E Corbelli","year":"2019","unstructured":"Corbelli\u00a0E, Miserocchi\u00a0E, Marchese\u00a0A et\u00a0al (2019) Ocular toxicity of mirvetuximab. Cornea 38(2):229\u2013232. https:\/\/doi.org\/10.1097\/ico.0000000000001805","journal-title":"Cornea"},{"issue":"8","key":"2306_CR28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00417-019-04337-8","volume":"257","author":"AL Kunkler","year":"2019","unstructured":"Kunkler\u00a0AL, Binkley\u00a0EM, Mantopoulos\u00a0D et\u00a0al (2019) Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol 257(8):1771\u20131781. https:\/\/doi.org\/10.1007\/s00417-019-04337-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2306_CR29","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jfo.2021.10.012","volume":"45","author":"L Vuillemey","year":"2022","unstructured":"Vuillemey\u00a0L, Goin\u00a0P, Kalbacher\u00a0E et\u00a0al (2022) Corneal toxicity of mirvetuximab soravtansine: a\u00a0case report. Article in French. J\u00a0Fr Ophtalmol 45(6):e263\u2013e264. https:\/\/doi.org\/10.1016\/j.jfo.2021.10.012","journal-title":"J Fr Ophtalmol"},{"key":"2306_CR30","volume-title":"Summary of product characteristics","author":"Elahere","year":"2024","unstructured":"Elahere (2024) Summary of product characteristics. AbbVie"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02306-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:31:57Z","timestamp":1759307517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02306-7"}},"subtitle":["Nebenwirkungen an der Augenoberfl\u00e4che im Zusammenhang mit dem auf Tubuline wirkenden Antik\u00f6rper-Wirkstoff-Konjugat Mirvetuximab-Soravtansin","A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine"],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02306-7","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Khoramnia und G. Schmidinger machen folgende Angaben: Vortrags- und Beratungst\u00e4tigkeit AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}